

CASE CT-2617-NP

CERTIFICATE OF MAILING

I hereby certify that the paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Nancy S. Turover  
Type or print name

*N. S. Turover*  
Signature

*Oct 9, 2003*  
Date

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: WU, ET AL.

APPLICATION NO: 10/620,240

FILED: July 15, 2003

FOR: PYRIDOPYRIMIDINE DERIVATIVES AS 5-HT<sub>6</sub> ANTAGONISTS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the filing date of the application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449. Copies of these references are enclosed herewith with the following exceptions: acknowledging the Examiner's direct request, U.S. patent(s) have been cited but not provided in hard copy because they are already readily available to the Examiner.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO-1449 form.

Respectfully submitted,

Aldo A. Algieri  
Agent for Applicants  
Reg. No. 31,697  
(203) 677-6809

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000

Date: 9 October 2003

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. CT-2617-NP


APPLICATION NO. 10/620,240

APPLICANT Wu, *et al.*

FILING DATE July 15, 2003

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,990,105	23 Nov 1999	Bös, <i>et al.</i>			
	AB	6,441,013	27 Aug 2002	Greiner, <i>et al.</i>			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AC	WO 0037452 *	29 Jun 2000	MERCK PATENT GMBH			<input checked="" type="checkbox"/>	<input type="checkbox"/>
	AD	EP 0 930 302 '	21 Jul 1999	F. HOFFMANN-LA ROCHE AG			<input type="checkbox"/>	<input type="checkbox"/>
	AE	EP 0 941 994 .	15 Sep 1999	F. HOFFMANN-LA ROCHE AG			<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS

	AF	Bentley, J. C., <i>et al.</i> , <u>British J. Pharm.</u> (1999) 126:1537-1542
	AG	Bourson, A. <i>et al.</i> , <u>J. Pharmacol. Exp. Ther.</u> (1995) 274(1):173-180
	AH	Monsma, F. J. <i>et al.</i> , <u>Mol. Pharmacol.</u> (1993) 43:320-327
	AI	Murata, S. <i>et al.</i> , <u>British J. of Pharmacol.</u> (1999) 127:19-26
	AJ	Rogers, D.C. and Hagan J.J., <u>Psychopharmacology</u> (2001) 158:114-119
	AK	Roth, B. L. <i>et al.</i> , <u>J. Pharmacol. Exp. Ther.</u> (1994) 268(3):1403-1410
	AL	Sleight, A. J. <i>et al.</i> <u>Behav. Brain Res.</u> (1996) 73: 245-248
	AM	Ward, R. P. <i>et al.</i> , <u>Neuroscience</u> (1995) 64(4):1105-1111
	AN	Woolley, M.L. <i>et al.</i> , <u>Neuropharmacology</u> (2001) 41:210-219
	AO	
	AP	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.